Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results

Ertan, Elif; Doğan, Mustafa; Polat, Onur; Efe, Neriman; Akdogan, Muberra; İnan, Sibel; Duman, Rahmi

doi:10.5935/0004-2749.20210036

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the injection times of 3-mg aflibercept in our study were greatly induced as compared to the report by Ertan et al [26] who used a 3 + PRN regimen with 9.09 ± 3.9 injections of aflibercept within 30 months for patients with wAMD not responding to 16.8 ± 8.8 injections of ranibizumab during 30.18 ± 16.78 months. In our series, the average number of injections was 3.7 in 6 months and 5.1 in 12 months.…”

Section: Discussionmentioning

confidence: 65%

Switching to the aflibercept (3 mg) therapy for treatment-resistant wet age-related macular degeneration: 1-year outcomes

Feng,

Chu,

Lin

et al. 2024

Medicine

View full text Add to dashboard Cite

This study aimed to elucidate 1-year outcomes following switching to the aflibercept (3 mg) therapy for treatment-resistant wet age-related macular degeneration (wAMD). In this prospective, open-label, non-controlled clinical trial, 18 patients with wAMD who had multiple recurrences or persistent exudation despite intravitreal injections of anti-vascular endothelial growth factor agents (except aflibercept) received a 3-mg intravitreal aflibercept injection every 4 weeks. Each patient received 3 to 8 injections. The central retinal thickness and fibrovascular pigment epithelial detachment height decreased significantly at 1 month after initiation of the aflibercept injection, and the values were 146 and 163.2 μm, respectively, at the final visit. The morphological improvement was sustained. The intraretinal and subretinal fluid was completely absorbed at the end of the follow-up. The logMAR vision increased from baseline 0.68 to 0.59 (P < .05). No ocular or systemic adverse events occurred. The intravitreal injection of 3-mg aflibercept seems to be feasible in the treatment of wAMD unresponsive to other anti-vascular endothelial growth factor agents.

show abstract

Section: Discussionmentioning

confidence: 65%

Switching to the aflibercept (3 mg) therapy for treatment-resistant wet age-related macular degeneration: 1-year outcomes

Feng,

Chu,

Lin

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…There are more reports in the literature about switching from ranibizumab to aflibercept, or from bevacizumab to aflibercept or ranibizumab than the other way around [7][8][9][10][11]. The results of these studies vary: some show the effectiveness of the switch in the form of anatomical improvement (CRT) and functional improvement (BCVA) [7,9,10]; others show anatomical improvement, but no changes in BCVA [8,10,11]. The SAFARI study, in which the authors assessed the effectiveness of the switch from aflibercept to ranibizumab, showed greater anatomical than functional improvement in the studied patients [12].…”

Section: Discussionmentioning

confidence: 99%

Switching Between Aflibercept and Ranibizumab in the Treatment of Refractory Exudative Age-related Macular Degeneration

2021

View full text Add to dashboard Cite

Introduction: Aflibercept and ranibizumab have become the most used drugs in the treatment of wet age-related macular degeneration. Some patients; however, do not respond to aflibercept and ranibizumab treatment. Our aim was to determine whether the switch from aflibercept to ranibizumab, and then switchback, is effective in a group of patients poorly responding to aflibercept. We assessed best corrected visual acuity, central retinal thickness, and the presence of intra- and subretinal fluid (respectively). Material and methods: We conducted a retrospective comparative case series study. Twenty eyes of 20 patients, who had no inhibition of disease activity after at least one year of treatment with aflibercept, were included in the study. If after switch to ranibizumab the response to the drug was again inadequate, we returned to aflibercept. We divided the study population into two groups: treatment- naïve and patients who had received injections before entering the Drug Program for the Treatment of Age-Related Exudative Macular Degeneration. Results: We observed an improvement in both best corrected visual acuity and central retinal thickness parameters, but only in the treatment-naïve group. We did not observe any statistically credible effects for sub- and intraretinal fluid in the studied groups. Conclusions: Drug conversion may be beneficial for patients poorly responding to primary therapy. Greater improvement is seen in previously untreated patients.

show abstract

Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results

Cited by 2 publications

References 0 publications

Switching to the aflibercept (3 mg) therapy for treatment-resistant wet age-related macular degeneration: 1-year outcomes

Switching to the aflibercept (3 mg) therapy for treatment-resistant wet age-related macular degeneration: 1-year outcomes

Switching Between Aflibercept and Ranibizumab in the Treatment of Refractory Exudative Age-related Macular Degeneration

Contact Info

Product

Resources

About